RSV Vaccination in Ireland: Balancing Infant Protection with Cost Concerns
Ireland stands at a crossroads in its fight against respiratory syncytial virus (RSV), a seasonal infection that hospitalizes thousands of infants and older adults each year. While new vaccines and immunizations show proven safety and effectiveness in reducing severe cases, their high cost has sparked debate about long-term affordability. The Health Information and Quality Authority (Hiqa) recently released a comprehensive assessment revealing that expanding RSV immunization could prevent hundreds of infant hospitalizations—but at a price tag that may strain public health budgets.
What the Hiqa Report Reveals
Hiqa’s health technology assessment, commissioned by the Department of Health, evaluated multiple immunization strategies for infants and older adults. Key findings include:
- Significant reductions in hospitalizations: All evaluated approaches—including maternal vaccines and monoclonal antibodies for infants—would substantially lower RSV-related hospital admissions.
- Safety and efficacy confirmed: No major safety concerns were identified for any of the immunization products reviewed.
- Cost barriers: Five-year implementation costs range from €15.6 million for a targeted maternal vaccine program to €70.6 million for broader adult vaccination.
Understanding RSV: A Seasonal Threat
Respiratory syncytial virus is a common viral infection affecting the lungs and airways. While most cases are mild, certain groups face higher risks:
Infants
- 7,000+ annual diagnoses in Ireland
- 1,800 hospital discharges and 130 ICU stays annually for children under 2
- Highest risk: babies under 1 year old
Older Adults
- 120+ annual hospital discharges for those 65+
- Highest mortality risk: adults 80+
The Affordability Dilemma
While the health benefits are clear, Hiqa’s assessment highlights significant financial challenges:
- Price uncertainty: Current costs (€165–€301 per dose) may decrease through competitive tendering, but no guarantees exist.
- Budget impact: The most comprehensive infant program (year-round monoclonal antibodies) would consume nearly 10% of Ireland’s annual vaccination budget.
- Waning effectiveness: Adult vaccines show reduced protection over time, potentially requiring booster doses.
“All RSV immunisation products considered were found to be safe and effective. However, the cost-effectiveness of long-term implementation remains uncertain at current prices.”
— Hiqa Health Technology Assessment, April 2026
Parental Concerns and Advocacy
The report has drawn mixed reactions from parents and health advocates:
- Support for protection: Many parents emphasize the emotional and financial toll of RSV hospitalizations, which can exceed €10,000 per case.
- Cost concerns: Others acknowledge the budget constraints, suggesting phased implementation or prioritization of high-risk groups.
- Calls for negotiation: Some advocate for government-led price negotiations with pharmaceutical manufacturers to improve affordability.
How Ireland Compares to Other Countries
Several nations have already implemented RSV immunization programs:
- Spain: Introduced a national monoclonal antibody program for infants in 2023, reporting a 70% reduction in hospitalizations.
- United States: Recommends maternal vaccination for pregnant women and monoclonal antibodies for high-risk infants, with costs partially covered by insurance.
- United Kingdom: Piloting a targeted program for premature infants and those with chronic conditions.
Ireland’s current approach remains limited to high-risk infants in hospital settings, leaving most of the population unprotected.
Frequently Asked Questions
What are the symptoms of RSV in infants?
Common signs include:
- Wheezing or difficulty breathing
- Persistent cough
- Fever (though not always present)
- Decreased appetite or lethargy
Severe cases may require oxygen support or ICU care. Seek medical attention if your infant shows signs of respiratory distress.
How do maternal vaccines work?
Maternal RSV vaccines are administered during pregnancy (typically in the third trimester). They stimulate the mother’s immune system to produce antibodies, which are then passed to the baby through the placenta. This provides protection during the first few months of life when infants are most vulnerable.
What’s the difference between a vaccine and a monoclonal antibody?
- Vaccine: Stimulates the body’s immune system to produce its own antibodies (used for maternal immunization).
- Monoclonal antibody: Provides ready-made antibodies directly to the infant, offering immediate but temporary protection (typically 4–6 months).
Will the HSE implement an RSV program?
The Department of Health is reviewing Hiqa’s assessment to determine next steps. Factors under consideration include:
- Budget availability
- Pharmaceutical pricing negotiations
- Potential phased rollout for highest-risk groups
A decision is expected later in 2026.
The Path Forward
Ireland’s RSV dilemma reflects a broader global challenge: how to balance life-saving medical advances with fiscal responsibility. While the vaccines and antibodies exist to dramatically reduce infant hospitalizations, their cost presents a formidable hurdle. As the Department of Health deliberates, key questions remain:
- Can Ireland negotiate more favorable pricing with manufacturers?
- Should the focus be on high-risk groups first, or is universal infant protection the goal?
- How will Ireland’s approach align with or diverge from other European nations?
For now, parents are advised to:
- Practice fine hand hygiene and respiratory etiquette
- Limit exposure to sick individuals during RSV season (typically October–March)
- Seek medical attention promptly if their infant shows signs of severe illness
As the conversation evolves, one fact remains clear: RSV is a preventable burden. The question is not whether Ireland can protect its most vulnerable, but how it will choose to do so within the constraints of its healthcare system.